JSTL Pharma LLP intends to establish a new bulk pharmaceuticals and intermediates facility in Kadechur, Kalaburagi, Karnataka. Capacity is 81.73 Tns per month for bulk pharmaceuticals and intermediates, and 60 Kilo ltrs per day for treated effluents. The project is estimated to cost approximately 17 billion rupees.Per year, the facility will be capable of producing 100 tonnes of bulk pharmaceuticals and intermediates. The pharmaceutical industry will make use of the drugs and intermediates. By the end of 2026, the project is anticipated to be completed. In India, JSTL Pharma LLP is the foremost producer of bulk pharmaceuticals and intermediates. The business has facilities in both Karnataka and Telangana.
The new bulk drugs and intermediates project is part of the company's strategy to expand its production capacity and meet the increasing demand for bulk drugs and intermediates in India. The endeavor is being financed with a mixture of debt and equity. A consortium of banks, managed by the State Bank of India, has arranged for the debt financing.announcment. The JSTL Pharma LLP promoters are providing the equity financing. JSTL Pharma LLP has made a significant investment in the new bulk drugs and intermediates initiative. It is anticipated that the project will boost the company's development and help it become a prominent player in India's bulk drugs and intermediates market.
Here are some additional details about the project: The project will be located in an industrial area in Kadechur, Kalaburagi. The plant will have a captive power plant to meet its energy requirements. The plant will use the latest technology for bulk drugs and intermediates production. The project is expected to generate direct and indirect employment for around 300 people. The new bulk drugs and intermediates project is a sign of the growing demand for bulk drugs and intermediates in India. The project is also a vote of confidence in the Indian economy.
As of September 2023, The project is currently in the stage of being approved currently awaiting approval from the government.
News by Rahul Yeligetti